Fig. 7: BLK knockdown reduces CSC characteristics. | Oncogenesis

Fig. 7: BLK knockdown reduces CSC characteristics.

From: Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells

Fig. 7

A Light and fluorescent microscopy of JN-DSRCT-1 and BER-DSRCT cells with dox-inducible shRNA to knockdown BLK or LCK. Cells were cultured in sphere conditions with or without dox for 7 days (scale bar = 100 µm). B Western blot of BLK and LCK expression in shBLK and shLCK cell lines with or without dox. C RT-qPCR analysis of NANOG, OCT4, SOX2, and KLF4 transcripts in JN-DSRCT-1 and BER-DSRCT shBLK cell lines with or without dox (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, student t test). D Western blot of SOX2 and NANOG protein expression in shBLK cell lines with or without dox. E Relative viability of JN-DSRCT-1 and BER-DSRCT cell lines treated with doxorubicin for 72 hours with or without dox to silence BLK expression (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ANOVA).

Back to article page